about
Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma.Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity.Efficacy and toxicity of therapy immediately after treatment with nivolumab in relapsed multiple myeloma.Minimal residual disease negativity in multiple myeloma is associated with intestinal microbiota composition
P50
description
researcher
@en
name
Alexander M Lesokhin
@en
type
label
Alexander M Lesokhin
@en
prefLabel
Alexander M Lesokhin
@en
P31
P496
0000-0001-9321-702X